NCT01582737View on ClinicalTrials.gov

Xarelto [SPAF] Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

11,310

Participants

Timeline

Start Date

May 30, 2012

Primary Completion Date

March 31, 2019

Study Completion Date

January 17, 2020

Conditions
Brain Ischemia
Interventions
DRUG

Rivaroxaban(Xarelto, BAY59-7939)

Patients treated with Xarelto under practical manner

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY